Substituted aminoquinolones as DGKalpha inhibitors for immune activation

US11998539B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE
• Deutsches Krebsforschungszentrum · DE

Inventors

• Norbert Schmees · Berlin, DE
• Lars Wortmann · Berlin, DE
• Dennis KIRCHHOFF · Berlin, DE
• Thi Thanh Uyen NGUYEN · Berlin, DE
• Nicolas Werbeck · Berlin, DE
• Ulf Bömer · Glienicke, DE
• Kirstin Petersen · Berlin, DE
• Christina KOBER · Lollar, DE
• Christian Lechner · Berlin, DE
• Dirk Kosemund · Berlin, DE
• Rienk Offringa · Leiden, NL
• Mareike GREES · Berlin, DE
• Benjamin Bader · Berlin, DE

Key dates

• Filing date: Nov 30, 2022
• Grant date: Jun 4, 2024
• Expiry date: Nov 30, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.